JP2009502937A - Ａｂｌキナーゼ阻害 - Google Patents

Ａｂｌキナーゼ阻害 Download PDF

Info

Publication number
JP2009502937A
JP2009502937A JP2008524094A JP2008524094A JP2009502937A JP 2009502937 A JP2009502937 A JP 2009502937A JP 2008524094 A JP2008524094 A JP 2008524094A JP 2008524094 A JP2008524094 A JP 2008524094A JP 2009502937 A JP2009502937 A JP 2009502937A
Authority
JP
Japan
Prior art keywords
compound
kinase
abl
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502937A5 (https=
Inventor
ジョン ポラード，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009502937A publication Critical patent/JP2009502937A/ja
Publication of JP2009502937A5 publication Critical patent/JP2009502937A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008524094A 2005-07-26 2006-07-26 Ａｂｌキナーゼ阻害 Pending JP2009502937A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70277105P 2005-07-26 2005-07-26
US78516106P 2006-03-23 2006-03-23
US83025706P 2006-07-12 2006-07-12
PCT/US2006/028984 WO2007014250A2 (en) 2005-07-26 2006-07-26 Abl kinase inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012122081A Division JP2012158616A (ja) 2005-07-26 2012-05-29 Ａｂｌキナーゼ阻害

Publications (2)

Publication Number Publication Date
JP2009502937A true JP2009502937A (ja) 2009-01-29
JP2009502937A5 JP2009502937A5 (https=) 2009-09-10

Family

ID=37683933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008524094A Pending JP2009502937A (ja) 2005-07-26 2006-07-26 Ａｂｌキナーゼ阻害
JP2012122081A Pending JP2012158616A (ja) 2005-07-26 2012-05-29 Ａｂｌキナーゼ阻害

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012122081A Pending JP2012158616A (ja) 2005-07-26 2012-05-29 Ａｂｌキナーゼ阻害

Country Status (6)

Country Link
US (1) US20090298844A1 (https=)
EP (1) EP1906967A4 (https=)
JP (2) JP2009502937A (https=)
AU (1) AU2006272609A1 (https=)
CA (1) CA2616517A1 (https=)
WO (1) WO2007014250A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372975T3 (es) * 2005-12-01 2012-01-30 Bristol-Myers Squibb Company Procedimientos de identificación y tratamiento de individuos que muestran cariotipos.
CA2658436A1 (en) * 2006-07-26 2008-01-31 Merck And Co., Inc. A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
JP6378171B2 (ja) 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2017335E (pt) * 2001-10-05 2011-03-02 Novartis Ag Domínios da cinase abl mutados
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
SG155222A1 (en) * 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes

Also Published As

Publication number Publication date
WO2007014250A3 (en) 2007-06-28
AU2006272609A1 (en) 2007-02-01
US20090298844A1 (en) 2009-12-03
CA2616517A1 (en) 2007-02-01
JP2012158616A (ja) 2012-08-23
EP1906967A4 (en) 2010-07-28
WO2007014250A2 (en) 2007-02-01
WO2007014250A8 (en) 2008-02-21
EP1906967A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
JP2012158616A (ja) Ａｂｌキナーゼ阻害
AU2011335882B2 (en) Treatment of JAK2-mediated conditions
JP2023512040A (ja) 化合物及びその使用
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
CA2632256A1 (en) Combination of an iap-inhibitor and a taxane7
EP4606801A1 (en) Fused heterocyclic compound and use thereof
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
EP2640718B1 (de) Substituiertes natrium-1h-pyrazol-5-olat
CN109641890B (zh) 异柠檬酸脱氢酶(idh)抑制剂
WO2018050108A1 (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
US12421221B2 (en) Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CA3224123A1 (en) Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
US8410096B2 (en) Antitumor agent, kit and method of treating cancer
CN101160130B (zh) 用于嗜酸粒细胞增多综合征的嘧啶基氨基苯甲酰胺衍生物
WO2026018023A1 (en) Synergistic combinations comprising lunbotinib for anti-cancer therapy
KR20240024933A (ko) 화합물이 골수섬유증 및 이의 관련 증상 또는 병증을 치료하기 위한 약물 제조에서의 응용 및 해당 화합물의 용도
HK40107546A (zh) 抑制PI3K同工型α的化合物和用於治疗癌症的方法
HK1196537A (en) N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl]-1h-indazol-6-ylsulfanyl)-benzamide for the treatment of chronic myelogenous leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120913